AI Article Synopsis
- Most patients with hepatocellular carcinoma (HCC) are diagnosed at late stages, necessitating systemic treatments, as the disease is often resistant to therapies.
- Significant progress has been made in molecular targeted therapy and immunotherapy, with drugs like regorafenib, cabozantinib, and ramucirumab approved for treatment after disease progression on sorafenib.
- While individual immunotherapies, such as nivolumab and pembrolizumab, showed limited success, combining targeted therapies with immune checkpoint inhibitors has produced more favorable outcomes, pointing to promising future directions for HCC treatment.
Article Abstract
The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage that can only benefit from systemic treatments. Although HCC is highly treatmentresistant, significant achievements have been made in the molecular targeted therapy and immunotherapy of HCC. In addition to regorafenib, cabozantinib and ramucirumab were approved for the second- line targeted treatment by the FDA after disease progression on sorafenib. Nivolumab failed to demonstrate remarkable benefit in overall survival (OS) as first-line therapy, while pembrolizumab did not achieve pre-specified statistical significance in both OS and progression-free survival (PFS) as second-line treatment. Combinations of targeted agents, immune checkpoint inhibitors and other interventions showed favorable results. In this review, we summarized the progress of systemic therapy in HCC and discussed the future directions of the treatment of HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1566523220666200628014530 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!